X-ray structure of the hRORα LBD at 1.63 Å: Structural and functional data that cholesterol or a cholesterol derivative is the natural ligand of RORα

Structure

Volumn 10, Issue 12, 2002, Pages 1697-1707

  Kallen, Joerg A ^a   Schlaeppi, Jean Marc ^a   Bitsch, Francis ^a   Geisse, Sabine ^a   Geiser, Martin ^a   Delhon, Isabelle ^a   Fournier, Brigitte ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

Author keywords

Atherosclerosis; Cholesterol; Co activator; Nuclear receptor; ROR; Transcription factor

Indexed keywords

CHOLEST 5 EN 3 BETA OL CHOLESTEROL; CHOLESTEROL; CHOLESTEROL DERIVATIVE; LIGAND; RETINOIC ACID RECEPTOR; RETINOIC ACID RELATED ORPHAN RECEPTOR ALPHA; UNCLASSIFIED DRUG; CELL RECEPTOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; RAR RELATED ORPHAN RECEPTOR A; RAR-RELATED ORPHAN RECEPTOR A; TRANSACTIVATOR PROTEIN;

ARTICLE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG TARGETING; HOMEOSTASIS; HUMAN; HUMAN CELL; LIGAND BINDING; PRIORITY JOURNAL; TRANSCRIPTION INITIATION; X RAY CRYSTALLOGRAPHY; CELL CULTURE; CHEMISTRY; DRUG EFFECT; ELECTROSPRAY MASS SPECTROMETRY; GENETIC TRANSCRIPTION; METABOLISM; PHYSIOLOGY; PROTEIN CONFORMATION;

CHOLESTEROL; CRYSTALLOGRAPHY, X-RAY; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIGANDS; LOVASTATIN; PROTEIN CONFORMATION; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 1842848068     PISSN: 09692126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-2126(02)00912-7     Document Type: Article

References (50)

1. Jetten A.M., Kurebayashi S., Ueda E. The ROR nuclear orphan receptor subfamily. critical regulators of multiple biological processes Prog. Nucleic Acid Res. Mol. Biol. 69:2001;205-247.
2. NRNC Nuclear Receptors Nomenclature Committee) Cell. 97:1999;161-163.
3. Carlberg C., van Huijsduijnen R.H., Staple J.K., DeLamarter J.F., Becker-Andre M. RZRs, a new family of retinoid-related orphan receptors that function as both monomers and homodimers. Mol. Endocrinol. 8:1994;757-770.
4. Andre E., Conquet F., Steinmayr M., Stratton S.C., Porciatti V., Becker-Andre M. Disruption of retinoid-related orphan receptor β changes circadian behaviour, causes retinal degeneration and leads to vacillans phenotype in mice. EMBO J. 17:1998;3867-3877.
5. Kurebayashi S., Ueda E., Sakaue M., Patel D.D., Medvedev A., Zhang F. Retinoid-related orphan receptor γ (RORγ) is essential for lymphoid organogenesis and controls apoptosis during thymopoiesis. Proc. Natl. Acad. Sci. USA. 97:2000;10132-10137.
6. Giguere V., Tini M., Flock G., Ong E., Evans R.M., Otulakowski G. Isoform-specific amino-terminal domains dictate DNA-binding properties of RORα, a novel family of orphan hormone nuclear receptors. Genes Dev. 8:1994;538-553.
7. McBroom L.D.B., Flock G., Giguere V. The nonconserved hinge region and distinct amino-terminal domains of the RORα orphan nuclear receptor isoforms are required for proper DNA bending and RORα-DNA interactions. Mol. Cell. Biol. 15:1995;796-808.
8. Vu-Dac N., Gervois P., Grötzinger T., De Vos P., Schoonjans K., Fruchart J.-C., Auwerx J., Mariani J., Tedgui A., Staels B. Transcriptional regulation of Apolipoprotein A-I gene expression by the nuclear receptor RORα J. Biol. Chem. 272:1997;22401-22404.
9. Raspé E., Duez H., Gervois P., Fievet C., Fruchart J.C., Besnard S., Mariani J., Tedgui A., Staels B. Transcriptional regulation of Apolipoprotein C-III gene expression by the orphan nuclear receptor RORα J. Biol. Chem. 276:2001;2865-2871.
10. Sundvold H., Lien S. Identification of a novel peroxisome proliferator-activated receptor (PPARγ) promoter in man and transactivation by the nuclear receptor RORα1. Biochem. Biophys. Res. Commun. 287:2001;383-390.
11. Hamilton B.A., Frankel W.N., Kerrebrock A.W., Hawkins T.L., FitzHugh W., Kusumi K., Russell L.B., Mueller K.L., van Berkel V., Birren B.W.et al. Disruption of the nuclear hormone receptor RORα in staggerer mice. Nature. 379:1996;736-739.
12. Steinmayr M., Andre E., Conquet F., Rondi-Reig L., Delhaye-Bouchaud N., Auclair N., Daniel H., Crepel F., Mariani J., Sotelo C.et al. Staggerer phenotype in retinoid-related orphan receptor α-deficient mice. Proc. Natl. Acad. Sci. USA. 95:1998;3960-3965.
13. Matsui T., Sashihara S., Oh Y., Waxman S.G. An orphan nuclear receptor, mRORα, and its spatial expression in adult mouse brain. Brain Res. Mol. Brain Res. 33:1995;217-226.
14. Trenkner E., Hoffmann M.K. Defective development of the thymus and immunological abnormalities in the neurological mouse mutation "staggerer." J. Neurosci. 6:1986;1733-1737.
15. Delerive P., Monte D., Dubois G., Trottein F., Fruchart-Najib J., Mariani J., Fruchart J.-C., Staels B. The orphan nuclear receptor RORα is a negative regulator of the inflammatory response. EMBO Rep. 21:2001;42-48.
16. Mamontova A., Seguret-Mace S., Esposito B., Chaniale C., Bouly M., Delhaye-Bouchaud N., Luc G., Staels B., Duverger N., Mariani J.et al. Severe atherosclerosis and hypoalphalipoproteinemia in the staggerer mouse, a mutant of the nuclear receptor RORα Circulation. 98:1998;2738-2743.
17. Meyer T., Kneissel M., Mariani J., Fournier B. In vitro and in vivo evidence for orphan nuclear receptor RORα function in bone metabolism. Proc. Natl. Acad. Sci. USA. 97:2000;9197-9202.
18. Jarvis C.I., Staels B., Brugg B., Lemaigre-Dubreuil Y., Tedgui A., Mariani J. Age-related phenotypes in the staggerer mouse expand the RORα nuclear receptor's role beyond the cerebellum. Mol. Cell. Endocrinol. 186:2002;1-5.
19. Wiesenberg I., Missbach M., Kahlen J.-P., Schräder M., Carlberg C. Transcriptional activation of the nuclear receptor RZRα by the pineal gland hormone melatonin and identification of CGP 52608 as a synthetic ligand. Nucleic Acids Res. 23:1995;327-333.
20. Lau P., Bailey P., Dowhan D.H., Muscat G.E.O. Exogenous expression of a dominant negative RORα1 vector in muscle cells impairs differentiation. RORα1 directly interacts with p300 and MyoD Nucleic Acids Res. 27:1999;411-420.
21. Atkins G.B., Hu X., Guenther M.G., Rachez C., Freedman L.P., Lazar M.A. Coactivators for the orphan nuclear receptor RORα Mol. Endocrinol. 13:1999;1550-1557.
22. Renaud J.P., Moras D. Structural studies on nuclear receptors. Cell. Mol. Life Sci. 57:2000;1748-1769.
23. Harris J.M., Lau P., Chen S.L., Muscat G.E.O. Characterization of the retinoid orphan-related receptor α coactivator binding interface. a structural basis for ligand-independent transcription Mol. Endocrinol. 16:2002;998-1012.
24. Greschick H., Wurtz J.-M., Sanglier S., Bourguet W., van Dorsselaer A., Moras D., Renaud J.-P. Structural and functional evidence for ligand-independent transcriptional activation by the estrogen-related receptor 3. Mol. Cell. 9:2002;303-313.
25. Stehlin C., Wurtz J.-M., Steinmetz A., Greiner E., Schüle R., Moras D., Renaud J.-P. X-ray structure of the orphan receptor RORβ ligand-binding domain in the active conformation. EMBO J. 20:2001;5822-5831.
26. Chawla A., Repa J.J., Evans R.M., Mangesldorf D.J. Nuclear receptors and lipid physiology. opening the X-files Science. 294:2001;1866-1870.
27. Repa J.J., Mangelsdorf D.J. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu. Rev. Cell Dev. Biol. 16:2000;459-481.
28. Laskowski R.A., MacArthur M.W., Moss D.S., Thornton J.M. Procheck. a program to check the stereochemical quality of protein structures J. Appl. Crystallogr. 26:1993;283-291.
29. Bourguet W., Ruff M., Chambon P., Gronemeyer H., Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-α Nature. 375:1995;377-382.
30. Wurtz J.M., Bourguet W., Renaud J.P., Vivat V., Chambon P., Moras D., Gronemeyer H. A canonical structure for the ligand-binding domain of nuclear receptors. Nat. Struct. Biol. 3:1996;87-94.
31. Nolte R.T., Wisely G.B., Westin S., Cobbs J.E., Lambert M.H., Kurokawa R., Rosenfeld M.G., Willson T.M., Glass C.K., Milburn M.V. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ Nature. 395:1998;137-143.
32. Jones T.A., Zou J.Y., Cowan S.W., Kjeldgaard M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A. 47:1991;110-119.
33. Bogan A.A., Cohen F.E., Scanlan T.S. Natural ligands of nuclear receptors have conserved volumes. Nat. Struct. Biol. 5:1998;679-681.
34. Rocchi S., Picard F., Vamecq J., Gelman L., Potier N., Zeyer D., Dubuquoy L., Bac P., Champy M.F., Plumnket K.D.et al. A unique PPARγ ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol. Cell. 8:2001;737-747.
35. Potier N., Lamour V., Poterszman A., Thierry J.C., Moras D., Van Dorsselaer A. Characterization of crystal content by ESI-MS and MALDI-MS. Acta Crystallogr. D. 56:2000;1583-1590.
36. Bourguet W., Vivat V., Wurtz J.M., Chambon P., Gronemeyer H., Moras D. Crystal structure of a heterodimeric complex of RAR and RXR ligand-binding domains. Mol. Cell. 5:2000;289-298.
37. Billas I.M.L., Moulinier L., Rochel N., Moras D. Crystal structure of the ligand-binding domain of the ultraspiracle protein USP, the ortholog of retinoid X receptors in insects. J. Biol. Chem. 276:2001;7465-7474.
38. Wisely G., Miller A., Davis R., Thornquest A., Johnson R., Spitzer T., Sefler A., Shearer B., Moore J., Miller A., Willson T., Williams S. Hepatocyte nuclear factor 4 is a transcription factor that constitutively binds fatty acids. Structure. 10:2002;1225-1234.
39. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature. 343:1990;425-430.
40. Brown M.S., Goldstein J.L. A proteolytic pathway that controls the cholesterol content of membranes, cells and blood. Proc. Natl. Acad. Sci. USA. 96:1999;11041-11048.
41. Shepherd J. Lipid lowering. statins and the future Heart Suppl. 1 84:2000;I46-I47.
42. Rothblat G.H., de La Llera-Moya M., Atger V., Kellner-Weibel G., Williams D.L., Phillips M.C. Cell cholesterol efflux. integration of old and new observations provides new insights J. Lipid Res. 40:1999;781-796.
43. Dhe-Paganon S., Duda K., Iwamoto M., Chi Y., Shoelson S.E. Crystal structure of the HNF4α ligand binding domain in complex with endogenous fatty acid ligand. J. Biol. Chem. 277:2002;37973-37976.
44. Nwokoro N.A., Wassif C.A., Forbes D.P. Genetic disorders of cholesterol biosynthesis in mice and humans. Mol. Genet. Metab. 74:2001;105-119.
45. Burckhard L., Zinkernagel R.M., Hengartner H. Arterial inflammation and atherosclerosis. Trends Cardiovasc. Med. 12:2002;154-159.
46. Otwinowski Z., Minor W. Processing of X-ray diffraction data collected in oscillation mode. Carter C.W. Jr., Sweet R.M. Methods in Enzymology, Volume 276. 1997;Academic Press, London. 307-326.pp.
47. Weeks C.M., Miller R. The design and implementation of SnB v2.0. J. Appl. Crystallogr. 32:1999;120-124.
48. Blessing R.H., Smith G.D. Difference structure-factor normalization for heavy-atom or anomalous-scattering substructure determinations. J. Appl. Crystallogr. 32:1999;664-670.
49. CCP4 Collaborative Computational Project 4) The CCP4 suite. programs for protein crystallography Acta Crystallogr. D. 50:1994;760-763.
50. Kleywegt G.J., Jones T.A. Detection, delineation, measurement and display of cavities in macromolecular structures. Acta Crystallogr. D. 50:1994;178-185.